Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27607410 | 0.82 | ALOX5 (0.47) | FAAHALOX5 | |
| SCHEMBL4425970 | 0.80 | KMT2A (0.44) | FAAHTDP1 | |
| SCHEMBL26015528 | 0.80 | ALDH1A1 (0.37) | ALDH1A1TP53CYP3A4ALOX15MAPK1 | |
| SCHEMBL2055559 | 0.79 | PTGS2 (0.48) | FAAHPTGS2ALDH1A1ALOX5CYP2D6 | |
| SCHEMBL8246986 | 0.79 | PTGS2 (0.48) | FAAHPTGS2ALDH1A1ALOX5CYP2D6 | |
| SCHEMBL2055557 | 0.79 | PTGS2 (0.48) | FAAHPTGS2ALDH1A1ALOX5CYP2D6 | |
| SCHEMBL27513027 | 0.79 | EPHX1 (0.42) | EPHX1PTGS2ALDH1A1TDP1ALOX5 | |
| SCHEMBL13185575 | 0.78 | TP53 (0.46) | FAAHPTGS2ALDH1A1TP53 | |
| SCHEMBL1203969 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TP53CYP3A4ALOX15MAPK1 | |
| SCHEMBL1203966 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TP53CYP3A4ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247550-B2 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | FAAH 487/4885EPHX1 2011/4885PTGS2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.